Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02040766 · ClinicalTrials.gov registry record · Phase 3
A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma
A Phase 3 study of Asthma, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 628
- Enrollment target
- 20
- Study locations
NCT02040766 is a Phase 3 study of Asthma that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 628 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (60% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT02040766, a Phase 3 study of Asthma, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 628 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized, double-blind, double-dummy, placebo-controlled, parallel-group, 12-week study will evaluate the efficacy and safety of beclomethasone dipropionate (80 or 160 mcg/day) administered via breath-actuated inhaler (BAI) and metered-dose inhaler (MDI) in pediatric patients 4 through 11 years of age with persistent asthma, compared with placebo. Patients took 1 inhalation (with assistance from parents/guardians/caregivers, as needed) from each of 2 devices (BAI device followed by MDI device in that order) twice daily as per the double-dummy study design: 1 BAI treatment or placebo device and 1 MDI treatment or placebo device for a total of 2 inhalations each time.
Conditions Studied
Interventions
- DRUG Placebo MDI
- DRUG Beclomethasone dipropionate BAI
- DRUG Placebo BAI
- DRUG albuterol/salbutamol 90 mcg
- DRUG Beclomethasone dipropionate MDI
Study Locations (20)
California
- Teva Investigational Site 10903 - Costa Mesa
- Teva Investigational Site 10911 - Downey
- Teva Investigational Site 10901 - Huntington Beach
- Teva Investigational Site 12297 - Huntington Beach
- Teva Investigational Site 10880 - Mission Viejo
- Teva Investigational Site 10895 - Orange
- Teva Investigational Site 10924 - Paramount
- Teva Investigational Site 10910 - Rolling Hills Estates
- Teva Investigational Site 12343 - Roseville
- Teva Investigational Site 12298 - San Diego
- Teva Investigational Site 12300 - San Diego
- Teva Investigational Site 12295 - San Jose
- Teva Investigational Site 12312 - West Covina
Alabama
- Teva Investigational Site 12346 - Hoover
- Teva Investigational Site 12294 - Montgomery
Colorado
- Teva Investigational Site 10937 - Centennial
- Teva Investigational Site 10899 - Colorado Springs
Arizona
- Teva Investigational Site 10925 - Phoenix
Arkansas
- Teva Investigational Site 12349 - Little Rock
Florida
- Teva Investigational Site 10894 - Aventura
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 628 participants |
| Start Date | 2013-12 |
| Est. Completion | 2016-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02040766
The ClinicalTrials.gov registry entry for NCT02040766 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 628 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (60% lower). The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 5 interventions - of which Placebo MDI is the first listed.
NCT02040766 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Alabama, Colorado.
Frequently Asked Questions
What is clinical trial NCT02040766 about?
NCT02040766 is a clinical study titled "A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma". This randomized, double-blind, double-dummy, placebo-controlled, parallel-group, 12-week study will evaluate the efficacy and safety of beclomethasone dipropionate (80 or 160 mcg/day) administered via breath-actuated inhaler (BAI) and metered-dose inhaler (MDI) in pediatric patients 4 through 11 yea...
What is the current status of trial NCT02040766?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 628 participants. The study started on 2013-12. Estimated completion is 2016-03.
What conditions does trial NCT02040766 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT02040766?
The interventions under investigation include: Placebo MDI (DRUG), Beclomethasone dipropionate BAI (DRUG), Placebo BAI (DRUG), albuterol/salbutamol 90 mcg (DRUG), Beclomethasone dipropionate MDI (DRUG).
Who is sponsoring clinical trial NCT02040766?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02040766 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.